Loading...
PCR logo

PCC Rokita SAWSE:PCR Stock Report

Market Cap zł1.4b
Share Price
zł68.30
My Fair Value
zł85.64
20.2% undervalued intrinsic discount
1Y-14.6%
7D1.5%
Portfolio Value
View

PCC Rokita SA

WSE:PCR Stock Report

Market Cap: zł1.4b

PCC Rokita (PCR) Stock Overview

Designs, produces, and sells chemical products in Poland and internationally. More details

PCR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends4/6

PCR Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

PCC Rokita SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for PCC Rokita
Historical stock prices
Current Share Pricezł68.30
52 Week Highzł80.50
52 Week Lowzł65.60
Beta0.79
1 Month Change1.04%
3 Month Change-2.43%
1 Year Change-14.63%
3 Year Change-12.66%
5 Year Change55.23%
Change since IPO105.97%

Recent News & Updates

Recent updates

Does PCC Rokita (WSE:PCR) Have A Healthy Balance Sheet?

Apr 29
Does PCC Rokita (WSE:PCR) Have A Healthy Balance Sheet?

Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

May 30
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Aug 24
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 29
PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Is PCC Rokita (WSE:PCR) A Risky Investment?

Jan 18
Is PCC Rokita (WSE:PCR) A Risky Investment?

PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Apr 16
PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Why We Like The Returns At PCC Rokita (WSE:PCR)

Mar 19
Why We Like The Returns At PCC Rokita (WSE:PCR)

What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

Jan 25
What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Sep 01
We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Jun 14
Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

May 18
Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Apr 13
Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

Mar 23
Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Mar 09
PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

Feb 19
Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Feb 04
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Jan 15
Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Dec 30
Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

Dec 17
Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Dec 03
PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Nov 20
Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Shareholder Returns

PCRPL ChemicalsPL Market
7D1.5%-0.7%0.01%
1Y-14.6%-6.6%32.7%

Return vs Industry: PCR underperformed the Polish Chemicals industry which returned -6.6% over the past year.

Return vs Market: PCR underperformed the Polish Market which returned 32.7% over the past year.

Price Volatility

Is PCR's price volatile compared to industry and market?
PCR volatility
PCR Average Weekly Movement2.3%
Chemicals Industry Average Movement3.0%
Market Average Movement4.5%
10% most volatile stocks in PL Market9.3%
10% least volatile stocks in PL Market3.0%

Stable Share Price: PCR has not had significant price volatility in the past 3 months compared to the Polish market.

Volatility Over Time: PCR's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19931,421Wieslaw Klimkowskiwww.pcc.rokita.pl

PCC Rokita SA designs, produces, and sells chemical products in Poland and internationally. It offers chlorine and alkali; polyurethane insulation systems; household chemicals and cleaning agents; washing preparations; liquid chemicals and disinfectants; vegan body and hair cleansing products; shower gels, hair shampoos, and liquid soaps; foams; and organic products, as well as polyols, naphthalene, and phosphorus derivatives. The company also provides specialty products, including anionic surfactants, alkoxylated fatty alcohols, non-ionic surfactants, synthetic and foam-forming extinguishing agents, synthetic base oils and additives, polyester polyols, chemical raw materials, polyurethane adhesives and prepolymers, polymeric polyols, and polyether polyols.

PCC Rokita SA Fundamentals Summary

How do PCC Rokita's earnings and revenue compare to its market cap?
PCR fundamental statistics
Market capzł1.36b
Earnings (TTM)zł105.21m
Revenue (TTM)zł1.91b
12.9x
P/E Ratio
0.7x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCR income statement (TTM)
Revenuezł1.91b
Cost of Revenuezł1.56b
Gross Profitzł348.08m
Other Expenseszł242.87m
Earningszł105.21m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)5.30
Gross Margin18.27%
Net Profit Margin5.52%
Debt/Equity Ratio38.2%

How did PCR perform over the long term?

See historical performance and comparison

Dividends

7.4%
Current Dividend Yield
95%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 14:14
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PCC Rokita SA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cezary BernatekErste Group Bank AG
Jakub SzkopekErste Group Bank AG
Adam MilewiczPKO BP Securities